CD274 and cancer: In 2018, radiomics was demonstrated to be associated with clinical outcomes of cancer patients treated with anti-PD-1 and anti-PD-L1 monotherapy in a retrospective multicohort study29 by Sun et al. Recently, Colen et al. found that a radiomics-based signature could predict the response to pembrolizumab in 57 patients with rare types of late-stage cancer with 94.7% accuracy, 97.3% sensitivity, and 90% specificity30.